Parathormone (Parathyroid Hormone)

Parathormone (PTH) testing is covered when used to evaluate suspected hyperparathyroidism or hypoparathyroidism, abnormal total calcium, differential diagnosis of hypercalcemia, monitoring of secondary hyperparathyroidism in CKD or post-renal transplant, postoperative follow-up after thyroid/parathyroid surgery, ectopic PTH–producing tumors, magnesium/vitamin D disturbances, or to assess osteoporosis. Testing frequency for CKD patients must follow K/DOQI guidance (stage 3: annually; stages 4–5 or dialysis: every 3 months); tests performed more frequently require documentation of specific symptoms, treatment noncompliance, or therapy changes and must meet CMS LCD and Medicare medical necessity rules.

"PTH testing is covered to evaluate patients with clinical signs or symptoms suggestive of hyperparathyroidism (e."

Sign up to see full coverage criteria, indications, and limitations.